Find here all the media resources that we feel is useful to share with the outside world.
Stay tuned with our news
Who we are
Keen Eye supports pharmaceutical companies along every step of drug development with AI digital assays within a scalable platform for computational pathology.
Our Mission is to support medical researchers to accelerate the delivery of the right drugs to the right patients, through the use of more standardised, reproducible and novel AI-driven insights.
Keen Eye closed series A fundraising
April 29, 2019, PARIS – KEEN EYE, a company that designs, develops and markets machine learning solutions for the research and biomedical sectors, announces today that it has finalized a EUR 6 million fundraising led by CM-CIC Innovation and with the Quadrivium 1 Seeding Fund, managed by Seventure Partners, its historical partner.
HalioDx and Keen Eye partner to empower IMMUNOSCORE® with AI
November 8, 2018, PARIS – HalioDx, an immuno-oncology diagnostic company pioneering the immunological diagnosis of cancers with Immunoscore® and Keen Eye, an innovative company specialized in image analysis technologies based on artificial intelligence announced today a strategic partnership to develop a cloud-based platform (...).
Iris Pharma and Keen Eye team up to bring AI in ophthalmology studies
October 2018, PARIS – Keen Eye, a French technology company specialized in image analysis for the life science industry, announced today a strategic partnership agreement with Iris Pharma, a world-wide leading ophthalmology-focused contract research organization (CRO) that offers preclinical and clinical drug / device development services.
Keen Eye raises €1.5 Million from Seventure Partners’ Quadrivium 1 seed fund
December 12, 2016, PARIS – Keen Eye will finalize the development of its innovative image interpretation platform for laboratories and biomedical research Keen Eye, a company that designs, develops and markets innovative image analysis solutions for research and the medical sector, announced today a 1.5 million fund raising from Seventure Partners’ Quadrivium seed fund.